Crinetics Pharmaceuticals (CRNX) Non-Current Assets (2017 - 2026)

Crinetics Pharmaceuticals has reported Non-Current Assets for 10 years, with the latest figure at $78.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 12.29% year-over-year to $78.9 million; the trailing twelve-month figure through Mar 2026 stood at $303.9 million (up 21.55% YoY), and the FY2025 full-year result was $77.9 million, up 31.6% from the prior year.
• Non-Current Assets for Q1 2026 stood at $78.9 million, up from $77.9 million in the prior quarter.
• The five-year high for Non-Current Assets was $78.9 million in Q1 2026, with the low at $5.0 million in Q1 2022.
• Average Non-Current Assets over 5 years is $46.1 million, with a median of $60.8 million recorded in 2024.
• Year-over-year, Non-Current Assets declined 12.34% in 2022 and surged 903.16% in 2023.
• Tracing CRNX's Non-Current Assets over 5 years: stood at $7.0 million in 2022, then soared by 775.29% to $61.2 million in 2023, then dropped by 3.26% to $59.2 million in 2024, then jumped by 31.6% to $77.9 million in 2025, then gained by 1.28% to $78.9 million in 2026.
• The last three Non-Current Assets figures came in at $78.9 million (Q1 2026), $77.9 million (Q4 2025), and $74.8 million (Q3 2025), per Business Quant data.

Peer Comparison